Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Dabrafenib/Trametinib Combo Approved by FDA for BRAF+ NSCLC
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has been approved by the FDA for the treatment of patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
iFCG Regimen Induces High Rate of Bone Marrow MRD Negativity in IGHV-Mutated CLL
The combination regimen of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of minimal residual disease-negative status in bone marrow as a first-line treatment in patients with IGHV-mutated chronic lymphocytic leukemia
Lenvatinib Improves PFS Over Sorafenib in Unresectable HCC
Treatment with lenvatinib in the first-line setting of unresectable hepatocellular carcinoma improved progression-free survival by 3.7 months and was noninferior for overall survival (OS) compared with sorafenib.
Subcutaneous Rituximab Approved by FDA for Blood Cancers
Subcutaneous rituximab has been approved by the FDA for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated CLL.
Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with MET exon 14-mutant non–small cell lung cancer.
View More >

Features

Third Daratumumab Triplet Approved by FDA for Multiple Myeloma
Third Daratumumab Triplet Approved by FDA for Multiple Myeloma
Daratumumab (Darzalex) has been approved by the FDA for use in combination with pomalidomide (Pomalyst) and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies.
Ceritinib Approved by the FDA for Frontline ALK+ NSCLC
Ceritinib (Zykadia) has been approved by the FDA for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer.
Nivolumab Granted FDA's Priority Review for Liver Cancer
Nivolumab (Opdivo) has been granted a priority review designation by the FDA for use as a treatment for patients with hepatocellular carcinoma (HCC) following prior sorafenib.
Entrectinib Granted Breakthrough Designation by FDA for NTRK+ Solid Tumors
Entrectinib has been granted breakthrough therapy designation by the FDA for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors.
Brigatinib Approved by FDA for ALK-Positive NSCLC
Brigatinib (Alunbrig) has been granted an accelerated approval by the FDA as a treatment for patients with metastatic ALK-positive non-small cell lung cancer who are resistant to prior crizotinib.
Publications